U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541638) titled 'Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases' on March 26.
Brief Summary: Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of internal organs. The most prevalent is interstitial lung disease (ILD), a severe pulmonary complication seen in 10 to 50% of CTDs and a major determinant of disability and death. Prevalence and clinical course of CTD-ILDs vary widely and seem to be independent of treatment. Current screening and prognosis prediction strategies based on clinical variabl...